These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 22482472)

  • 21. Pharma allowed to make own genetics.
    Owens J
    Nat Rev Drug Discov; 2005 Jul; 4(7):530. PubMed ID: 16075483
    [No Abstract]   [Full Text] [Related]  

  • 22. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 23. Commentary: can we talk? About Food and Drug Regulation and the First Amendment.
    Cohen MN
    Food Drug Law J; 2003; 58(4):741-56. PubMed ID: 15027458
    [No Abstract]   [Full Text] [Related]  

  • 24. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 25. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 26. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 27. Raising the bar. Barcoding has the potential to dramatically reduce medication errors.
    Goth G
    Healthc Inform; 2006 Apr; 23(4):38-41. PubMed ID: 16676641
    [No Abstract]   [Full Text] [Related]  

  • 28. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 29. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 32. Names in vain.
    Vazquez E; Whitfield L
    Posit Aware; 1997; 8(6):13. PubMed ID: 11364853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Best buy drugs: many common generics beat brand names.
    Consum Rep; 2011 Mar; 76(3):24-7. PubMed ID: 21434454
    [No Abstract]   [Full Text] [Related]  

  • 34. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 36. America's drug problem.
    Philpott S
    Hastings Cent Rep; 2012; 42(4):9-10. PubMed ID: 22777971
    [No Abstract]   [Full Text] [Related]  

  • 37. AstraZeneca takes legal action to delay generic quietiapine in US.
    Hawkes N
    BMJ; 2012 Mar; 344():e2099. PubMed ID: 22422864
    [No Abstract]   [Full Text] [Related]  

  • 38. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 39. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
    Rostron A
    Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biotech industry struggles with generics approval.
    Knight J
    Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.